Checkpoint Therapeutics’ (CKPT) “Hold” Rating Reiterated at Lake Street Capital

Lake Street Capital reaffirmed their hold rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report report published on Monday morning, Marketbeat Ratings reports. The brokerage currently has a $4.10 price objective on the stock, down from their prior price objective of $7.00.

CKPT has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th. D. Boral Capital reissued a “buy” rating and set a $4.80 price objective (down from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday.

Checkpoint Therapeutics Trading Down 0.5 %

Shares of CKPT opened at $3.98 on Monday. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The firm has a market capitalization of $194.36 million, a P/E ratio of -2.16 and a beta of 1.41. The firm’s 50-day moving average is $3.13 and its two-hundred day moving average is $3.10.

Insider Activity at Checkpoint Therapeutics

In other news, CEO James F. Oliviero III sold 220,230 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. This represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William Garrett Gray sold 268,432 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. The trade was a 20.63 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 582,336 shares of company stock worth $2,156,801. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CKPT. 683 Capital Management LLC acquired a new stake in shares of Checkpoint Therapeutics in the 4th quarter worth about $522,000. Geode Capital Management LLC raised its position in Checkpoint Therapeutics by 41.2% in the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after acquiring an additional 124,787 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Checkpoint Therapeutics during the fourth quarter valued at approximately $374,000. Bank of America Corp DE boosted its stake in shares of Checkpoint Therapeutics by 30,216.8% during the 4th quarter. Bank of America Corp DE now owns 90,041 shares of the company’s stock worth $288,000 after acquiring an additional 89,744 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after buying an additional 80,000 shares during the period. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.